Sigilon Therapeutics, Inc. (SGTX)
followers
·
Follow
Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Rogério V. Coelho
Employees:
70
100 BINNEY STREET, STE 600, CAMBRIDGE, MA, 02142
617-336-7540
Date | Ratio |
---|---|
2023-05-23 | 1:13 |
Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of mucopolysaccharidosis type 1.
All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
---|